Using SIRT1 Activators to Treat Tuberculosis
By: Richard Liang 18’ Tuberculosis (TB) is a highly infectious disease that can remain dormant for many years. Currently, treatment options are limited by Mycobacterium tuberculosis’s ability evade the immune system and mutate into drug-resistant strains. Outbreaks are a more pressing concern in developing countries, where health care is less accessible. In a recent study led by Catherine Y. Cheng from the Singapore … Continue reading Using SIRT1 Activators to Treat Tuberculosis

